“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

(2021) Ajay K Nooka et al.   Future Oncology

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

(2021) Matteo C. Da Vià et al.   NATURE MEDICINE

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

(2021) Mehmet Kemal Samur et al.   Nature Communications

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma

(2021) Ahsan Wahab et al.   Frontiers in Oncology

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

(2021) Sagar Lonial et al.   CANCER

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

(2021) Rocio Montes de Oca et al.   MOLECULAR CANCER THERAPEUTICS

Effective anti-BCMA retreatment in multiple myeloma

(2021) Nicolas Gazeau et al.   Blood Advances

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

(2021) Suzanne Trudel et al.   BLOOD

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).

(2020) Saad Zafar Usmani et al.   JOURNAL OF CLINICAL ONCOLOGY

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

(2020) Meletios Dimopoulos et al.   LANCET

Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients

(2020) Rebecca B. Bausell et al.   Eye & Contact Lens-Science and Clinical Practice

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

(2019) Suzanne Trudel et al.   Blood Cancer Journal

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells

(2019) Haiming Chen et al.   LEUKEMIA RESEARCH

Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

(2019) Katja Weisel et al.   BLOOD

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

(2019) Michel Attal et al.   LANCET

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

(2018) Suzanne Trudel et al.   LANCET ONCOLOGY

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma

(2016) Lydia Lee et al.   BRITISH JOURNAL OF HAEMATOLOGY

γ-secretase directly sheds the survival receptor BCMA from plasma cells

(2015) Sarah A. Laurent et al.   Nature Communications

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY